Grand Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

El CEO de Grand Pharmaceutical Group's es Chao Zhou, nombrado en Jun 2021, tiene una permanencia de 2.83 años. posee directamente un 0.008% de las acciones de la empresa, con un valor de HK$1.12M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 4.1 años, respectivamente.

Información clave

Chao Zhou

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.9yrs
Participación del CEO	0.008%
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt

Apr 26

Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)

Apr 08

Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching

Mar 24

If You Had Bought China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Shares Five Years Ago You'd Have Earned 332% Returns

Mar 11

Are Robust Financials Driving The Recent Rally In China Grand Pharmaceutical and Healthcare Holdings Limited's (HKG:512) Stock?

Feb 22

China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Are Growing But Is There More To The Story?

Jan 21

CEO

Chao Zhou (33 yo)

2.9yrs

Permanencia

Mr. Chao Zhou serves as Executive Deputy Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 2019 and serves as its Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Weikun Tang	Executive Chairman	2.9yrs	HK$2.91m	0.012% HK$ 1.9m
Linda Shi	Executive Director	2.9yrs	HK$1.01m	sin datos
Chao Zhou	CEO, Executive Deputy Officer & Executive Director	2.9yrs	sin datos	0.0075% HK$ 1.2m
Liu Hu	Investor Relations Director	no data	sin datos	sin datos
Guang Yang	Executive Director	less than a year	sin datos	sin datos
Tin Chung Foo	Company Secretary	12.7yrs	sin datos	sin datos
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	sin datos	sin datos
Xiaojie Chen	Vice President	no data	sin datos	sin datos

2.9yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 512 se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Weikun Tang	Executive Chairman	2.9yrs	HK$2.91m	0.012% HK$ 1.9m
Linda Shi	Executive Director	2.9yrs	HK$1.01m	sin datos
Chao Zhou	CEO, Executive Deputy Officer & Executive Director	less than a year	sin datos	0.0075% HK$ 1.2m
Guang Yang	Executive Director	less than a year	sin datos	sin datos
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	sin datos	sin datos
Tosi Wan So	Independent Non-Executive Director	19.2yrs	HK$209.00k	sin datos
Yebi Hu	Independent Non-Executive Director	5.4yrs	HK$116.00k	sin datos
Geng Pei	Independent Non-Executive Director	13yrs	HK$70.00k	sin datos
Guofan Xie	Director of Grand Pharm (China)	30.3yrs	sin datos	sin datos
Zhang Bangguo	Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited	no data	sin datos	sin datos

4.2yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 512 se considera experimentada (4.1 años de antigüedad promedio).

Grand Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Executive Chairman recently bought HK$381k worth of stock

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Recent updates

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Executive Director recently bought HK$535k worth of stock

Upcoming dividend of HK$0.11 per share

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020)

Less than half of directors are independent

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 21% undervalued after recent price drop

Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration

Investor sentiment deteriorated over the past week

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million.